Skip to content
All articles

Multicenter phase 2 study of BVAC-C plus durvalumab for recurrent or metastatic cervical cancer

Prof. Chel Hun Choi
Prof. Chel Hun Choi

Immune checkpoint inhibitors show limited efficacy in previously treaten recurrent or metastatic cervical cancer (RMCC). BVAC-C is an autologous B cell-based and monocyte-based therapeutic vaccine targeting HPV 16/18 E6 and E7 oncoproteins. A multicenter phase 2 trial in South Korea evaluated the combination of BVAC-C and durvalumab for HPV18/18-positive rmCC after progression on platinum-based chemotherapy. Thirty patients received treatment; 29 were evaluable for efficacy. The objective response rate (ORR) was 37.9% (six complete responses and five partial responses) and the disease control rate was 62.1%. The 6-month progression-free survival (PFS) rate was 51.7% and median PFS was 8.7 months (95% CI 4.0-24.3). Patients with a treatment-free interval longer than 6 months achieved significantly higher ORR (52.9% versus 16.7%; p=0.047). The median duration of response was 20 months, and complete responders showed sustained remission beyond 18 months, raising the possibility of functional cure in a subset of patients. The authors conclude that second-line BVAC-C plus durvalumab showed encouraging antitumor activity with a manageable safety profile among patients with rmCC.

Original publicationjitc.bmj.com
Read the publication